REGENXBIO Added to Russell 2000(R) Index

ROCKVILLE, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) — REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced the company was...